Lilly Soars 6% Pre-Market After Q2 EPS Crushes Estimates at $8.38
LLY sits 88% above its 52-week low of $623.78.
Summary
Eli Lilly delivered a massive Q2 earnings beat, reporting adjusted EPS of $8.38 against a $6.31 consensus — a 33% surprise. Shares jumped 6% pre-market, adding to the obesity-drug momentum from recent positive trial data and expanded insurance coverage. The beat reinforces the blockbuster trajectory of Mounjaro and Zepbound, already driving exceptional revenue growth. With the FY revenue guide raised to $85B-$87B earlier today, the quarter confirms demand is outstripping even bullish expectations. The company also lifted its FY guidance and raised its 2026 sales outlook, driven by Mounjaro and Zepbound Q2 sales.
At the time of this announcement, LLY was trading at $1,170.05 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,249.45. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Binance News.